CSL (ASX:CSL) Reaches New 12-Month High at $235.66

Share on StockTwits

CSL Limited (ASX:CSL) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as A$235.66 ($167.13) and last traded at A$232.89 ($165.17), with a volume of 1092210 shares traded. The stock had previously closed at A$219.50 ($155.67).

The company has a market cap of $103.85 billion and a PE ratio of 57.73. The company has a debt-to-equity ratio of 95.80, a current ratio of 2.93 and a quick ratio of 1.46. The company has a 50-day moving average of A$223.17 and a 200 day moving average of A$205.05.


CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.

See Also: What type of investment options does a Roth IRA provide?

Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.